H. Lundbeck (WBAG:LUN) - Cotización, noticias y análisis

Resumen de acción LUN

H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally.

Acerca de la empresa

LUN fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	4/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Recompensas

Cotiza un 69.1% por debajo de nuestra estimación de su valor justo

Se prevé un crecimiento anual de los beneficios de 26.72%

Análisis de riesgos

Los accionistas han sido diluidos sustancialmente en el último año

Los márgenes de beneficio (6.8%) son inferiores a los del año pasado (12.1%)

Grandes partidas extraordinarias que afectan a los resultados financieros

Competidores de H. Lundbeck A/S

Organon

NYSE:OGN

US$5.0b

GlaxoSmithKline Pharmaceuticals

BSE:500660

₹354.7b

Aspen Pharmacare Holdings

JSE:APN

R101.3b

Livzon Pharmaceutical Group

SZSE:000513

CN¥32.4b

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for H. Lundbeck
Historical stock prices
Current Share Price	kr.23.20
52 Week High	kr.26.99
52 Week Low	kr.19.77
Beta	0
1 Month Change	0%
3 Month Change	5.89%
1 Year Change	-8.84%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-19.14%

Noticias y actualizaciones recientes

Recent updates

Rentabilidad de los accionistas

	LUN	AT Pharmaceuticals	Mercado AT
7D	0%	-1.3%	1.3%
1Y	-8.8%	6.9%	5.1%

Rentabilidad vs. Industria: LUN obtuvo unos resultados inferiores a los del sector Austrian Pharmaceuticals , que el año pasado arrojó un rendimiento del 3.4%.

Rentabilidad vs. Mercado: LUN obtuvo unos resultados inferiores a los del mercado Austrian, que fue del 2.2% el año pasado.

Volatilidad de los precios

Is LUN's price volatile compared to industry and market?
LUN volatility
LUN Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	5.1%
Market Average Movement	3.5%
10% most volatile stocks in AT Market	5.1%
10% least volatile stocks in AT Market	1.7%

Precio estable de las acciones: LUN no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: Datos insuficientes para determinar el cambio de volatilidad de LUN en el último año.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
1915	5,353	Deborah Dunsire	www.lundbeck.com

Resumen de fundamentos de H. Lundbeck A/S

¿Cómo se comparan los beneficios e ingresos de H. Lundbeck con su capitalización de mercado?
Estadísticas fundamentales de LUN
Capitalización bursátil	€4.77b
Beneficios(TTM)	€148.98m
Ingresos (TTM)	€2.20b

31.1x

Ratio precio-beneficio (PE)

2.1x

Ratio precio-ventas (PS)

¿Está LUN sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de LUN
Ingresos	kr.16.40b
Coste de los ingresos	kr.3.51b
Beneficio bruto	kr.12.89b
Otros gastos	kr.11.78b
Beneficios	kr.1.11b

Últimos beneficios comunicados

Mar 31, 2022

Próxima fecha de beneficios

Aug 17, 2022

Beneficios por acción (BPA)	1.12
Margen bruto	78.59%
Margen de beneficio neto	6.76%
Ratio deuda/patrimonio	32.2%

¿Cómo se ha desempeñado LUN a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción LUN

Recompensas

Análisis de riesgos

Competidores de H. Lundbeck A/S

NYSE:OGN

US$5.0b

BSE:500660

₹354.7b

JSE:APN

R101.3b

SZSE:000513

CN¥32.4b

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Lundbeck and Otsuka submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD

Otsuka Pharmaceutical Europe Ltd. and H. Lundbeck A/S Announces Approval in the EU for the Maintenance Treatment of Schizophrenia

H. Lundbeck A/S Announces Management Appointments

H. Lundbeck A/S Announces Potential First-In-Class Therapy for Migraine Prevention Enters Advanced Clinical Stage

H. Lundbeck A/S Proposes Dividend for the Accounting Year 2023

H. Lundbeck A/S Appoints Dianne Holto as EVP, People & Organization, Effective from April 1, 2024

Recent updates

Lundbeck and Otsuka submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD

Otsuka Pharmaceutical Europe Ltd. and H. Lundbeck A/S Announces Approval in the EU for the Maintenance Treatment of Schizophrenia

H. Lundbeck A/S Announces Management Appointments

H. Lundbeck A/S Announces Potential First-In-Class Therapy for Migraine Prevention Enters Advanced Clinical Stage

H. Lundbeck A/S Proposes Dividend for the Accounting Year 2023

H. Lundbeck A/S Appoints Dianne Holto as EVP, People & Organization, Effective from April 1, 2024

Lundbeck Announces Supportive Phase II Results with Lu Af82422 in the Treatment of Multiple System Atrophy from the Amulet Trial

H. Lundbeck A/S to Report Nine Months, 2024 Results on Nov 13, 2024

H. Lundbeck A/S, Annual General Meeting, Mar 20, 2024

H. Lundbeck A/S Announces New Clinical Data Supporting the Efficacy and Tolerability of Lu AG09222 for the Preventive Treatment of Migraine At the International Headache Congress 2023 in Seoul, Korea

Lundbeck and Otsuka Announce Topline Results from Two Phase III Trials of Brexpiprazole as Combination Therapy with Sertraline for the Treatment of Post-Traumatic Stress Disorder in Adults

H. Lundbeck A/S Announces Elise Hauge Executive Vice President, People and Communication Decides to Depart

H. Lundbeck A/S to Report Q4, 2023 Results on Feb 07, 2024

H. Lundbeck A/S Raises Earnings Guidance for the Year 2023

H. Lundbeck A/S Appoints Charl Van Zyl as New President

H. Lundbeck A/S Announces New Data Confirming Long-Term Benefit of Treatment with Vyepti® (Eptinezumab) in Migraine Prevention

H. Lundbeck A/S and Otsuka Pharmaceutical, Co. Ltd. Announce U.S. Food and Drug Administration Approval of sNDA for Rexulti®? (Brexpiprazole) for the Treatment of Agitation Associated with Dementia Due to Alzheimer's Disease

H. Lundbeck A/S Proposes Dividend for 2022

H. Lundbeck A/S Provides Earnings Guidance for the Financial Year 2023

H. Lundbeck A/S Appoints Thomas Gibbs as Executive Vice President and Head of Lundbeck in United States

Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S Announce FDA Acceptance and Priority Review of sNDA for Brexpiprazole for the Treatment of Agitation Associated With Alzheimer’s Dementia

H. Lundbeck A/S to Report Nine Months, 2023 Results on Nov 08, 2023

H. Lundbeck A/S, Annual General Meeting, Mar 21, 2023

H. Lundbeck A/S (Lundbeck)Announces Positive Data Showing Trintellix/Brintellix® (vortioxetine)

Otsuka and Lundbeck Announce U.S. FDA Acceptance of New Drug Application for Aripiprazole 2-Month, Ready-To-Use, Long-Acting Injectable to Treat Schizophrenia and Bipolar I Disorder in Adults

H. Lundbeck A/S Provides Earnings Guidance for the Financial Year 2022

H. Lundbeck A/S Revises Earnings Guidance for the Fiscal Year 2022

H. Lundbeck A/S and Otsuka Pharmaceutical Announce Positive Results Showing Reduced Agitation in Patients with Alzheimer's Dementia Treated with Brexpiprazole

European Medicines Agency Commences Review of Aripiprazole 2-Month Long-Acting Injectable for the Maintenance Treatment of Schizophrenia in Adult Patients Stabilised with Aripiprazole

H. Lundbeck A/S Announces Results from the Deliver Study with Vyepti

H. Lundbeck A/S(CPSE:LUN) dropped from OMX Nordic All-Share Index

H. Lundbeck A/S Common Stock to Be Deleted from OTC Equity

First quarter 2022 earnings released: EPS: kr.2.07 (vs kr.3.13 in 1Q 2021)

H. Lundbeck A/S Provides Earnings Guidance for the Year 2022

Less than half of directors are independent

H. Lundbeck A/S Completes Global Phase Iv, Randomized, Comparative Study Exploring the Role of Vortioxetine

H. Lundbeck A/S Appoints Joergornstein as Member of Lundbeck's Executive Management

Lundbeck to Present New Data at AAN 2022 Adding to Clinical Evidence Regarding VYEPTI

Less than half of directors are independent

Upcoming dividend of kr.2.00 per share

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

H. Lundbeck A/S Proposes Dividend for the Year 2021

EU Commission Approves Vyepti[®] (Eptinezumab) for the Preventive Treatment of Migraine in Adults

Otsuka and Lundbeck Announce FDA Approval of Supplemental New Drug Application for REXULTI® (brexpiprazole) to Treat Schizophrenia in Pediatric Patients Ages 13-17

Third quarter 2021 earnings released: EPS kr.1.62 (vs kr.2.38 in 3Q 2020)

Second quarter 2021 earnings released: EPS kr.1.90 (vs kr.2.93 in 2Q 2020)

First quarter 2021 earnings released: EPS kr.3.13 (vs kr.0.76 in 1Q 2020)

H. Lundbeck A/S Provides Revenue Guidance for the Full Year of Fiscal 2021

H. Lundbeck A/S Announces New Study Finds That Vortioxetine Helps Patients with MDD and Comorbid Generalized Anxiety Disorder

Independent Director has left the company

H. Lundbeck A/S Appoints Tarek Samad as Head of Research, Effective on May 1, 2021

H. Lundbeck A/S Announces Resignation of Henrik Andersen from Board

Full year 2020 earnings released: EPS kr.7.95 (vs kr.13.42 in FY 2019)

New 90-day high: €33.92

Revenue misses expectations

New 90-day high: €28.98

Rigshospitalet and Lundbeck Announce Partnership to Find New Ways to Treat Brain Diseases

Lundbeck Announces European Medicines Agency Acceptance of Marketing Authorization Application for Eptinezumab for the Prevention of Migraine

H. Lundbeck A/S Revises Earnings Guidance for the Fiscal Year 2020